Effects of blocking GABA degradation on corticotropin-releasing hormone gene expression in selected brain regions. by Tran, V et al.
UC Irvine
UC Irvine Previously Published Works
Title





















eScholarship.org Powered by the California Digital Library
University of California
Effects of Blocking GABA Degradation on Corticotropin-
Releasing Hormone Gene Expression in Selected Brain Regions
Viet Tran, Carolyn G. Hatalski, Xiao-Xin Yan, and Tallie Z. Baram
Departments of Pediatrics and Anatomy/Neurobiology, University of California at Irvine, Irvine,
California, U.S.A.
Summary
Purpose—The γ-aminobutyric acid (GABA) degradation blocker γ-vinyl-GABA (VGB) is used
clinically to treat seizures in both adult and immature individuals. The mechanism by which VGB
controls developmental seizures is not fully understood. Specifically, whether the anticonvulsant
properties of VGB arise only from its elevation of brain GABA levels and the resulting activation
of GABA receptors, or also from associated mechanisms, remains unresolved. Corticotropin-
releasing hormone (CRH), a neuropeptide present in many brain regions involved in
developmental seizures, is a known convulsant in the immature brain and has been implicated in
some developmental seizures. In certain brain regions, it has been suggested that CRH synthesis
and release may be regulated by GABA. Therefore we tested the hypothesis that VGB decreases
CRH gene expression in the immature rat brain, consistent with the notion that VGB may decrease
seizures also by reducing the levels of the convulsant molecule, CRH.
Methods—VGB was administered to immature, 9-day-old rats in clinically relevant doses,
whereas littermate controls received vehicle.
Results—In situ hybridization histochemistry demonstrated a downregulation of CRH mRNA
levels in the hypothalamic paraventricular nucleus but not in other limbic regions of VGB-treated
pups compared with controls. In addition, VGB-treated pups had increased CRH peptide levels in
the anterior hypothalamus, as shown by radioimmunoassay.
Conclusions—These findings are consistent with a reduction of both CRH gene expression and
secretion in the hypothalamus, but do not support an indirect anticonvulsant mechanism of VGB
via downregulation of CRH levels in limbic structures. However, the data support a region-
specific regulation of CRH gene expression by GABA.
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γ-Aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the central nervous
system. The actions of GABA on the GABAA receptor suppress the initiation and
propagation of seizures (1). Therefore drugs activating GABAA receptors or elevating
GABA levels in the synaptic cleft by blocking the breakdown of this neurotransmitter or its
reuptake have anticonvulsant properties (2). For example, the GABA transaminase blocker,
γ-vinyl-GABA (VGB; vigabatrin), has been efficacious for seizures in adults as well as in
infants and children (3,4). VGB also has been particularly useful for seizures that are age
specific to the developmental period, such as infantile spasms (5,6). Indeed, the response to
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VGB treatment, which results in a dose-dependent elevation of brain GABA (7), is often
significantly superior to the response to agents that activate GABA receptors directly (5).
Therefore it is unclear whether the mechanism by which VGB controls developmental
seizures involves solely GABA elevation and the consequent augmented inhibition in
neuronal circuits, or other mechanisms related to enhanced brain GABA levels such as age-
specific inhibition of production or secretion of excitatory neurotransmitters or
neuromodulators.
A candidate proconvulsant mechanism in the developing brain is enhancement of glutamate-
mediated excitation by the peptide corticotropin-releasing hormone (CRH). CRH has been
shown essentially to “amplify” the excitatory input of glutamate to the hippocampal circuit,
leading to epileptiform output (8). In addition, picomolar amounts of CRH have been shown
to induce prolonged limbic seizures involving amygdala and hippocampus (9,10). These
proconvulsant effects of CRH are largely age specific to the developmental period (11).
In the developing and mature brain, CRH functions as a neuromodulator in limbic circuits
involved in mediating the response to stress, as well as in learning and memory functions
(12,14). The peptide is highly expressed in brain regions associated with developmental
seizures, such as hippocampus and amygdala (15,16). In addition, in vitro and recent in vivo
studies suggested that CRH synthesis and secretion may be influenced by neurotransmitters
such as GABA (17,18). This study used an immature animal model to determine whether the
anticonvulsant effects of VGB may be mediated also by reduced expression of the
convulsant molecule CRH.
MATERIALS AND METHODS
Animals and tissue preparation
All experiments were conducted in accordance with NIH guidelines for the care and use of
laboratory animals and were approved by the Institutional Animal Care Committee. Timed-
pregnancy Sprague–Dawley-derived rats (Zivic-Miller, Zelienople, PA, U.S.A.) were
maintained in an NIH-approved animal facility on a 12-h light/dark cycle. In all, 36 animals
were used in the following experiments. Controls included in each experiment were
littermates of experimental pups. All pups were subjected to an intraperitoneal injection of
either VGB (500 mg/kg) or an identical volume of vehicle, between 8 and 10 a.m. on
postnatal day 9, to prevent potential diurnal variability in CRH–messenger RNA (mRNA)
levels (19). Pups were then observed for an hour on a euthermic pad, and then returned to
their home cages. Rats were permitted to survive for 24 h, a time point when VGB-induced
brain GABA levels are maximal (20).
For immunocytochemistry, rats were perfused with 4% buffered paraformaldehyde, as
described in detail elsewhere (15,21). For in situ hybridization histochemistry and for
radioimmunoassay analysis of CRH, rats were decapitated within minutes of removal from
home cages to minimize stress-related alteration of CRH expression (22,23). Brains were
rapidly removed and subjected to one of two procedures. For sectioning and in situ
hybridization, brains were frozen on powdered dry ice; for regional quantitation of CRH,
brains were dissected on ice as described (23). Trunk blood was collected for evaluation of
adrenocorticotropic hormone (ACTH) and corticosterone.
Immunocytochemistry
Matched sections from control and VGB-treated rats, spanning the rostrocaudal extent of the
cerebrum, were immunostained for GAD-67 on slide or free floating, by using a
modification of the standard Vector ABC protocol, as previously described (15). Sections
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from control and experimental brains were processed under identical conditions (on the
same slide or in the same well).
In brief, after several washes with phosphate-buffered saline (PBS), sections were treated
with 0.05% hydrogen peroxide for quenching endogenous peroxidase activity, and then
preincubated in PBS containing 5% normal goat serum and 1.5% bovine serum albumin for
blocking non-specific reactivity (PBS+). Sections were then incubated in a solution of
polyclonal GAD-67 antibody, made in rabbit (Chemicon Inc., Temecula, CA, U.S.A.; final
dilution, 1:5,000) in PBS+ containing 0.03% Triton-X-100, overnight at room temperature.
After several rinses with PBS, sections were transferred to a solution containing 1%
biotinylated goat anti-rabbit immunoglobulin G (IgG) with Triton-X-100 for 1 h at room
temperature, followed by a 1-h incubation in 1% ABC solution (Vectastain; Vector
Laboratories, Burlingame, CA, U.S.A.). The immunoreaction product was visualized by
using 0.005% hydrogen peroxide and 0.05% 3,3 diaminobenzidine (DAB) with 0.5% NiCl
enhancement.
In situ hybridization histochemistry (ISH)
ISH for detection of CRH–mRNA was performed as described previously (22-24). In brief,
20-μm coronal sections were collected on gelatin-coated slides and stored at −80°C. For
ISH, tissue sections were thawed, air-dried, fixed in 4% buffered paraformaldehyde,
dehydrated, and rehydrated through graded ethanols (22). Sections were exposed to 0.25%
acetic anhydride in 0.1 M triethanolamine and dehydrated. Prehybridization (1 h) and
hybridization (20 h) steps were performed at 40°C in a humidified chamber (22,24), by
using a deoxyoligonucleotide probe complementary to the coding region of CRH–mRNA
and 3′-end-labeled with 35S-dATP, at 3–4 × 105 cpm/section (24). Sections were then
washed and apposed to film (Hyperfilm β-Max; Amersham, IL, U.S.A.) for 5–7 days.
Selected sections also were dipped in emulsion (NTB-2; Eastman Kodak, Rochester, NY,
U.S.A.) and exposed for 3–4 weeks.
Acquisition and quantitative analysis of CRH-mRNA ISH signal
Semiquantitative analysis of CRH–mRNA was performed after in situ hybridization (22,23).
Digitized images of each brain were acquired by using a Studiostar scanner (AGFA,
resolution 1,200 × 1,200 dots per inch) and analyzed by using the ImageTool software
program (University of Texas Health Science Center, San Antonio, TX, U.S.A.; version
1.25). Densities were calibrated by using 14C standards and are expressed in μCi/g after
correcting for background by subtracting the density of the hybridization signal over the
corpus callosum. Anatomically matched sections from the hypothalamic paraventricular
nucleus (PVN; six sections with highest signal per brain), central nucleus of amygdala
(ACE), cingulate cortex, and hippocampus (CA 1, CA3a, CA3b) were analyzed from at least
three brains per group. The significance of observed quantitative differences among
experimental groups was evaluated by using the unpaired Student’s t test with Welch’s
correction for unequal variance as needed.
Analysis of CRH peptide
Immediately after decapitation, brains were microdissected to isolate the medial basal
hypothalamus (containing the median eminence and arcuate nucleus) and the anterior
hypothalamus (containing paraventricular, suprachiasmatic, and supraoptic nuclei, as well as
the anterior hypothalamic and medial preoptic areas). Tissue blocks were placed
individually in microfuge tubes and frozen in powdered dry ice. CRH peptide was purified
by a modification of a previously described procedure (25). In brief, tissue was thawed in
extraction buffer [0.25N HCI, 0.25N acetic acid, 4.5 μg/ml pepstatin A (Sigma, St. Louis,
MO, U.S.A.) and 0.5% β-mercaptoethanol] at 48°C for 3 min followed by homogenization
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(10 strokes with micro tissue grinder; Kontes, Vineland, NJ, U.S.A.) on ice. The
homogenate was sonicated (15 s at 75% power of 0.8 duty cycle of Braun sonicator) a total
of 4 times on ice. The preparation was centrifuged at 15,600 g for 30 min at 4°C. The
supernatant was transferred to a new tube, the centrifugation was repeated, and the
supernatant was desiccated to near dryness in a speed-vac. The preparation was resuspended
in 400 μl of assay buffer (26) containing 1 μg/ml of phenol red and the pH was adjusted to
7.2–7.6 using NaOH.
Radioimmunoassay (RIA) for CRH peptide was performed as previously described (26)
with slight modifications. Assay was performed in polypropylene RIA tubes (Fisher) with
rabbit anti-rat CRH antibody (kindly provided by W. Vale, final dilution of 1:700,000)
and 125I-Tyr-rat/human CRH (New England Nuclear; 30,000 cpm/tube). Calibrations to
CRH standards were performed by using 1:l serial dilutions of CRH (Bachem, Torrance,
CA, U.S.A.) ranging from 2,000 to 0.25 pg. The final precipitation was achieved by using
Pansorbin (Calbiochem, La Jolla, CA, U.S.A.; final dilution, I:360).
Plasma hormone measurement
Plasma concentrations of ACTH and of corticosterone were determined by RIA by using
commercial kits (Incstar, Stillwater, MN, and ICN, Irvine, CA, U.S.A., for ACTH and
corticosterone, respectively).
RESULTS
Behavioral effects of VGB
Administration of VGB (500 mg/kg) did not lead to acute behavioral alterations compared
with vehicle-injected controls. However, within 3–4 h of VGB treatment, pups became
drowsy. VGB-treated rats were still asleep at 24 h after receiving VGB, but maintained
normothermia and were observed to be groomed by the mother. However, they did not
suckle, and lost an average of 2–3 g of their body weight during the 24 h after VGB
administration.
Levels of the GABA-synthesizing enzyme, GAD-67
Because regional quantitation of GABA levels in the same brains analyzed for CRH
expression and release is problematic, analysis of the abundance of the GABA-synthesizing
enzyme was used as an indirect measure of GABA levels (27). GABA, via end-product
inhibition. is known to down-regulate the expression of glutamic acid decarboxylase (GAD),
the GABA-synthetic enzyme (27). Therefore immunocytochemistry for the GAD isoform,
GAD-67, was used to study changes in the GABA system in the cerebral cortex after VGB
treatment. GAD-67 immunoreacrivity was reduced in VGB-treated rats as compared with
controls (Fig. 1). This included disappearance of GAD-67 immunoreactive neurons in the
neocortex, leaving only a reduced number of labeled cells in the superficial layers.
Furthermore, GAD-67 immunolabeling in the neuropil of the cortex, cingulate, piriform, and
entorhinal cortical regions was lighter in the VGB-treated than control brains (data not
shown).
CRH–mRNA levels after VGB treatment
Quantitative analysis performed after in situ hybridization showed that CRH–mRNA levels
in the hypothalamic PVN of VGB-treated pups were significantly lower than those of
controls. To validate this analysis, two evaluation techniques were used: with the average
value of all sections for each brain as an independent variable (leading to n = three to four
per group), CRH–mRNA levels in VGB-treated rats was 0.1017 μCi/g, whereas that of
controls was 0.2104 μCi/g (p < 0.05). When analyzing values directly from each section.
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(leading to n = 18–24 per group, see Fig. 2), CRH–mRNA in VGB-treated rats was 0.1017
μCi/g, whereas that of controls was 0.2079 μCi/g (p < 0.001; Fig. 2). Dark-field
photomicrographs of PVN of control rats and those injected with VGB are shown in Fig. 3,
demonstrating substantial reduction of CRH–mRNA expression in matched sections of the
parvocellular PVN after VGB treatment. CRH–mRNA levels in the central nucleus of the
amygdala, hippocampus, and cingulate cortex of VGB-treated rats were not significantly
different from those in controls (Fig. 5).
CRH peptide levels after VGB treatment
RIA was used to measure the amount of the peptide, CRH, in the anterior hypothalamus
(containing the paraventricular, suprachiasmatic, and supraoptic nuclei) and in the medial–
basal hypothalamus (containing the median eminence and the arcuate nucleus). CRH peptide
levels in the anterior hypothalamus of VGB-treated pups were significantly higher than the
controls (p < 0.05; Fig. 4). In contrast, CRH peptide levels in the medial-basal hypothalamus
were not affected by VGB treatment (not shown).
Plasma hormone levels after VGB treatment
Plasma ACTH and corticosterone levels were measured by RIA. Pups treated with VGB had
significantly higher plasma corticosterone levels as compared with saline-treated controls (p
< 0.05; Fig. 6A). The apparent increase of plasma ACTH levels of VGB-treated pups was
not statistically significant (p < 0.1; Fig. 6B).
DISCUSSION
This study was designed to test the influence of GABA on CRH gene expression in specific
brain regions of the developing rat brain. The major findings of the study are (a) VGB
treatment under the experimental conditions of this study downregulated GAD-67
expression, consistent with elevated GABA levels; (b) VGB treatment resulted in lower
levels of CRH–mRNA in the hypothalamic PVN but not in the limbic regions analyzed; (c)
levels of the peptide CRH were higher in anterior hypothalamus of VGB-treated rats
compared with controls; and (d) VGB treatment led to increased plasma corticosterone
without significant alteration of ACTH levels.
VGB blocks GABA degradation by inhibiting both neuronal and glial GABA transaminase
(28). With in vivo magnetic resonance spectroscopy, VGB administration has been shown to
increase brain GABA levels in the human (29). For example, a single oral dose of 50 mg/kg
resulted in a 40% increase in GABA over baseline within 2 h, and a 60% increase by 24 h
(7,20). Thus in the adult, both a dose effect and a time effect of VGB on brain GABA have
been found, with presumed maximal inhibition of GABA transaminase with ~100 mg/kg of
VGB, and peak GABA accumulation at 24 h after administration (7,20). In the developing
human, the recommended VGB doses for long-term treatment of seizures is 100–150 mg/kg/
day (5), and in a series of three children, increased brain GABA have been reported (30).
The VGB dose used in this study for immature rats (500 mg/kg) is comparable to clinically
useful doses when calculated per body surface area, and the effect of this dose was assessed
at the 24-h point, predicted to coincide with maximal brain GABA levels.
Alterations in GABA levels after VGB treatment were examined indirectly, by using
immunocytochemistry detection of the GABA-synthesizing enzyme, GAD-67. This
permitted estimates of both GABA abundance and CRH–mRNA levels on adjacent sections
from the same experimental or control brain. Decreased brain GAD levels have been
documented after VGB-induced brain GABA levels (27). Thus the reduction of GAD
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immunoreactivity found in our study, is consistent with increased brain GABA due to VGB-
induced blocking of GABA transaminase (7,27).
Modulation of GABA is anticipated to influence CRH gene expression and secretion in key
limbic regions of the developing brain. In hippocampus, both in Ammon’s horn and the
dentate gyrus, a robust population of CRH-expressing neurons has been shown to consist of
GAB-Aergic interneurons (15,31). Colocalization of CRH with GAD-65 and GAD-67
isoforms has been documented in virtually all of these neurons (15). Colocalization of CRH
and GABA also has been demonstrated in a minority of CRH-expressing neurons of the
hypothalamic PVN (32). However, most CRH-expressing neurons in the PVN contain
neither the GABA-synthesizing enzyme GAD nor GABA (32,33). In addition, evidence for
inhibitory input to CRH-expressing neurons via GABAergic innervation has been
documented (32,34). To test whether the increased GABA associated with VGB treatment
influenced CRH gene expression, in situ hybhdization was performed to measure steady-
state levels of CRH–mRNA in limbic and hypothalamic regions. In addition, the relatively
high levels of CRH peptide present in hypothalamus permitted quantitative analysis of CRH
peptide with RIA.
VGB-treated rats were found to have a reduced level of CRH–mRNA in the PVN compared
with the controls. This is consistent with a reduction of CRH gene expression by enhanced
GABAergic receptor activation. Downregulation of CRH-mRNA levels was confined to the
hypothalamus; there were no alterations of CRH gene expression in other brain regions
(cingulate cortex, hippocampus, and amygdala) in response to VGB treatment. Because
colocalization of CRH and GABA is found in hippocampus and cortex, but not
hypothalamus, this finding suggests that the differential regiona1 regu1ation of CRH by
GABAergic mechanisms is not mediated by autoinhibition of double-transmitter CRH–
GABA neuronS by GABA.
Whereas VGB administration resulted in decreased CRH–mRNA levels in PVN, increased
peptide levels were detected in tissue blocks consisting mainly of the PVN (with additional
hypothalamic regions virtually devoid of CRH). Increased CRH peptide levels might be due
to increased synthesis. However, this is unlikely in the face of reduced CRH-message levels.
Alternatively, increased CRH peptide denotes inhibited secretion along axons leading to the
median eminence and into the bloodstream (32). This possibility is supported by several in
vitro studies showing that CRH secretion from hypothalamic slices is inhibited by GABA
(17,35).
Aside from administration of VGB, other experimental procedures and manipulations used
in this study are stressful and may therefore influence CRH synthesis and levels in the
hypothalamus of the immature rat (22,23). For example, separation from the mother is a
stressful circumstance, as is an intraperitoneal injection (22,36,37). However, the
experimental design accounted for these variables by using litter-matched controls that were
separated from the mother concurrent with the experimental group, received vehicle
injection, and were killed with the VGB group. In addition, to eliminate potential diurnal
variability in the levels of CRH–mRNA (19), all injections took place between 8 and 10 a.m.
and timed killing was precisely at 24 h. Therefore it is unlikely that stress resulting directly
from the experimental manipulations accounted for the differences in CRH–mRNA or CRH
peptide levels between VGB-treated and control groups.
However, as mentioned earlier, VGB led to drowsiness followed by prolonged sleep. This
resulted in lack of suckling and of food intake in the experimental group. Whether food
deprivation for 24 h influences CRH–mRNA levels in the PVN has not been fully settled.
Smith et al. (38) reported that maternal separation for 24 h—which is associated with food
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deprivation—decreased CRH–mRNA levels in the PVN. However, work from our
laboratory (36), confirmed by other investigators (39), indicated that 24 h of food
deprivation did not alter levels of CRH–mRNA in the PVN. Therefore we conclude that the
decreased or absent suckling in VGB-treated rats is unlikely to account fully for the
reduction in CRH–mRNA expression found in this study. In addition, food deprivation
associated with separation from the mother for 24 h has been shown to elevate plasma
corticosterone levels (36,37). Reinstitution of food intake via gavage restored plasma
corticosterone to baseline levels (37). Plasma ACTH levels, which directly depend on CRH
secretion, are not increased under the circumstances of maternal separation and food
deprivation (37,40). Thus it is generally considered that the elevation of plasma
corticosterone levels associated with lack of food intake (observed also in this study) is
mediated via an effect on adrenal sensitivity to ACTH rather than modulation of CRH
secretion.
In summary, VGB administration to immature rats depressed CRH gene expression in the
hypothalamus but not in the hippocampus, amygdala, or cortex. Therefore it is concluded
that an anticonvulsant effect of VGB via decreased CRH-mediated excitation is unlikely.
However, a region-specific effect of VGB on the CRH neuron is demonstrated, which
suggests alterations in the ability of VGB-treated humans to mount a hormonal response to
stressful stimuli.
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VGB-induced reduction of GABA-synthesizing enzyme (GAD-67) abundance, consistent
with elevation of GABA levels. Low-power view of immunoreactivity for glutamicacid-
decarboxylase isoform GAD-67 in infant rat neocortex, showing the effect of VGB on GAD
expression. A, B: From homologous portions of the parietal cortex of a 10-day-old control
rat and its VGB-treated littermate, respectively. GAD-67 immunoreactive neurons are seen
in all six cortical layers–indicated by roman numerals–of the control section (A). Abundance
of GAD-67–immunolabeled cell bodies is substantially reduced after VGB treatment (B).
WM, white matter. (Original magnification, ×100).
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CRH–mRNA levels in the hypothalamic paraventricular nucleus (PVN) are decreased after
VGB treatment. Quantitative analysis of autoradiograms of coronal sections (six per brain)
at the level of the hypothalamus subjected to in situ hybridization for CRH–mRNA. Signal
over the paraventricular nucleus (PVN) was quantified by using densitometric analysis.
Values are expressed as mean ± SEM of 18–24 values per group. Significance of difference
from vehicle-treated controls was determined by using the unpaired t test with Welch’s
correction: *p < 0.001.
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CRH–mRNA hybridization signal in the PVN is reduced after VGB treatment. Dark-field
photomicrographs of the hypothalamic paraventricular region of control (A) and VGB-
treated rats (B). Animals were killed 24 h after injections of saline (A) or VGB (B). Coronal
sections at the level of the PVN were subjected to in situ hybridization by using an
oligodeoxynucleotide probe directed at CRH–mRNA. The sections were dipped in emulsion
and developed together (see text for details). A significant reduction in CRH–mRNA signal
intensity is evident after VGB treatment. (Original magnification, ×200)
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CRH peptide levels in anterior hypothalamus are increased by VGB treatment. Quantitative
analysis of CRH peptide in the microdissected paraventricular and adjacent hypothalamic
nulcei was achieved by using RIA. Rats were killed 24 h after saline or VGB treatment.
Values are expressed as the mean CRH peptide content per rat, as obtained from five rats per
group. Error bars represent the standard error of the mean. *Significantly different from
saline controls (p < 0.05).
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CRH–mRNA levels in central amygdala, hippocampus, and cingulate cortex are unchanged
after VGB treatment. Quantitative analysis of autoradiograms of sections subjected to in situ
hybridization for CRH–mRNA in amygdala, hippocampus, and cingulate cortex. Values are
expressed as the mean ± SEM of at least four values per region per group. CRH–mRNA
levels in these regions were not significantly different from those of vehicle-treated controls
(p > 0.1).
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Plasma corticosterone but not ACTH levels are elevated after VGB treatment. Twenty-four
hours after treatment of saline or VGB, corticosterone (A), and adrenocorticotropic hormone
(ACTH, B) in trunk blood were measured by RIA. Bars represent the mean of three rats per
group with error bars indicating SEM. In A, *p < 0.05, as determined by unpaired Student’s
t test with Welch’s correction.
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